

11 April 2023

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001  
INDIA

Email: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

Dear Sirs

### **DISCLOSURE OF HOLDINGS**

In accordance with the regulatory requirements of Securities and Exchange Board of India (the “SEBI”), we wish to make disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Please be advised that the clients’ portfolios managed by HSBC Global Asset Management (Hong Kong) Limited being the investment adviser, hold 3.04% of the paid-up share capital or voting capital of Glenmark Pharmaceuticals Ltd collectively, as detailed in the enclosed disclosure form. Should you have any queries, please e-mail to [global\\_disclosures\\_of\\_interest@hsbc.com](mailto:global_disclosures_of_interest@hsbc.com).

Sincerely



Sanjeev Kalha  
Global Head, Global Disclosures of Interest  
HSBC Group Management Services Ltd

Encs

**Format for Disclosures under Regulation 29(2) of Securities and Exchange Board of India  
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	Glenmark Pharmaceuticals Ltd		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	HSBC Global Asset Management (Hong Kong) Limited		
Whether the acquirer belongs to Promoter/Promoter group	NA		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange Bombay Stock Exchange		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<p><b>Before the acquisition under consideration, holding of:</b></p> <p>a) Shares carrying voting rights  b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)  c) Voting rights (VR) otherwise than by shares  d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)  e) Total (a+b+c+d)</p>	<p>a) 8,813,840 = Total</p>	3.12%	
<p><b>Details of the acquisition/sale</b></p> <p>a) Shares carrying voting rights acquired/sold  b) VRs acquired/sold otherwise than by shares  c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired  d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)  e) Total (a+b+c+/-d)</p>	<p>a) 215,973 = Total</p>	0.07%	

<p><b>After the acquisition/sale, holding of:</b></p> <p>a) Shares carrying voting rights  b) Shares encumbered with the acquirer  c) VRs otherwise than by shares  d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition  e) Total (a+b+c+d)</p>	<p>a)  8,597,867  = Total</p>	<p>3.04%</p>	
<p>Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer, etc.)</p>	<p>Open Market Disposal</p>		
<p>Date of acquisition / sale of shares / VR/ date of receipt of intimation of allotment of shares, whichever is applicable</p>	<p>06 April 2023</p>		
<p>Equity share capital / total voting capital of the TC before the said acquisition / sale</p>	<p>282,168,156</p>		
<p>Equity share capital/total voting capital of the TC after the said acquisition / sale</p>	<p>282,168,156</p>		
<p>Total diluted share/voting capital of the TC after the said acquisition / sale</p>			

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

**Signature of the acquirer / seller / Authorised Signatory**

Place: United Kingdom

Date: 11 April 2023

**Note:**



Sanjeev Kalha  
(Authorized Signatory)

Global Head, Global Disclosure of Interest  
HSBC Group Management Services Ltd